Lisbeth Barkholt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisbeth Barkholt has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A. Porcellini
1 shared publication- Alberto Zambelli
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
1 shared publication C. Bengala
1 shared publicationD. Blaise
1 shared publicationD. Niederwieser
1 shared publicationG. Massenkeil
1 shared publication
Latest Publications
- Open Access
- 30 July 2007
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (7) , 683-689
Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
- 30 July 2007
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (7) , 683-689
Open AccessCyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
- Open Access
- 28 April 2006
- Published by Elsevier in Annals of Oncology
- Vol. 17 (7) , 1134-1140
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months. Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), 70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%. Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.
- 28 April 2006
- Published by Elsevier in Annals of Oncology
- Vol. 17 (7) , 1134-1140
Open AccessAllogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from 21 European centres. Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were given to 42 patients. The median follow-up was 15 (range 3–41) months. Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), 70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%. Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.
- 15 June 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (11) , 1475-1476
Tailoring a Homeostatic Expansion to Favor Donor Hematopoiesis
In the past, it has been thought to be necessary to eradicate existing host marrow stem cells before infusing donor hematopoietic cells, a technique called total myeloablation. This would open up the extracellular microenvironment of the bone marrow, that is, the niches, for marrow hematopoiesis after transendothelial migration of stem cells (1, 2). This hypothesis that marrow engraftment is determined by ‘space' in the bone marrow is supported by the clinical experience in patients with severe combined immunodeficiency (SCID). High levels of donor B- and T-cell reconstitution are usually achieved, but the myeloid and erythroid hematopoiesis continues to be of host origin (3). In recent animal and human studies, engraftment of allogeneic hematopoietic stem cells (HSC) has been successful after reducing intensity conditioning (RIC) regimens using minimal-to-moderate pretreatment of the host (4, 5). In these models, engraftment has been successful by infusing high numbers of donor cells, cells that compete with resident or residual marrow cells. In addition, the use of monoclonal antibodies or other specific methods to deplete host alloreactive T cells in vivo before transplantation has nearly abrogated the need for myeloablation. Consequently, the extent and kinetics of engraftment of donor hematopoietic stem cells after RIC correlates to the homeostatic competition between recipient and donor stem cells rather than the geographic ‘space' in the bone marrow. In this volume of Transplantation, Laylor et al. (6) examine the influence of interactive mechanisms in establishing a successful allogeneic hematopoietic stem cell engraftment. They used a murine model (C57BL/6 strain) of RIC and allogeneic hematopoietic stem cell transplantation (HSCT) in which male bone marrow transplanted into female recipient mice induce a host-versus-graft (HvG) reaction against the male specific minor histocompatibility antigen HY. In this system, engraftment could be monitored by RT-PCR and anti-HvG specific effector CD8+ cells using MHC class I tetramer technique. The amount of irradiation therapy prior to HSCT inhibited the generation of HvG effector CD8+ cells in a dose-response fashion. Stable engraftment was achieved following irradiation with 400 cGy but was only temporarily measured at day 14 postHSCT using 200 cGy. The dose-dependent effect of irradiation suggests that donor specific host cells with particular radiosensitivity must be eliminated for successful engraftment. In addition, numbers of HY-specific (anti-donor) CD8+ cells correlated inversely with levels of donor cell engraftment (9.3% [range 4.5–22.5] vs. 1.5% [range 0–7.6] in non-chimeric and chimeric recipients, respectively; P=0.007). The functional competence of HvG effectors was studied in vitro using splenocytes from female C57BL/6 mice transplanted with syngeneic male bone marrow that were stimulated with irradiated male splenocytes. After 7 days of culture, the numbers of HY-specific IFNγ producing CD8+ T cells were greatly expanded in recipients that rejected male bone marrow. Cultured splenocytes from recipients rejecting male bone marrow effectively killed target cells in antigen-specific manner. Neither HY-specific T-cell expansion nor killing was observed when splenocytes from chimeric recipients were assessed. Thus, clear correlation was found between the presence of mixed chimerism and the absence of HvG with engraftment. One would suggest a clonal deletion mechanism for HvG tolerance, but the contribution of regulatory T cells cannot be excluded. The authors also demonstrated that persistent chimerism was associated with tolerance to a second donor graft of hematopoietic or non-hematopoietic (donor type skin) origin. This tolerance was specific since a third party skin graft from CBA/Ca H2k strain was rejected. In addition, by using a congenic strain of mice it was shown that engrafted recipients not only maintained significant proportions of endogenous T cells, but these cells retained functional competence to third party transplantation antigens.
- 15 June 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (11) , 1475-1476
Tailoring a Homeostatic Expansion to Favor Donor Hematopoiesis
In the past, it has been thought to be necessary to eradicate existing host marrow stem cells before infusing donor hematopoietic cells, a technique called total myeloablation. This would open up the extracellular microenvironment of the bone marrow, that is, the niches, for marrow hematopoiesis after transendothelial migration of stem cells (1, 2). This hypothesis that marrow engraftment is determined by ‘space' in the bone marrow is supported by the clinical experience in patients with severe combined immunodeficiency (SCID). High levels of donor B- and T-cell reconstitution are usually achieved, but the myeloid and erythroid hematopoiesis continues to be of host origin (3). In recent animal and human studies, engraftment of allogeneic hematopoietic stem cells (HSC) has been successful after reducing intensity conditioning (RIC) regimens using minimal-to-moderate pretreatment of the host (4, 5). In these models, engraftment has been successful by infusing high numbers of donor cells, cells that compete with resident or residual marrow cells. In addition, the use of monoclonal antibodies or other specific methods to deplete host alloreactive T cells in vivo before transplantation has nearly abrogated the need for myeloablation. Consequently, the extent and kinetics of engraftment of donor hematopoietic stem cells after RIC correlates to the homeostatic competition between recipient and donor stem cells rather than the geographic ‘space' in the bone marrow. In this volume of Transplantation, Laylor et al. (6) examine the influence of interactive mechanisms in establishing a successful allogeneic hematopoietic stem cell engraftment. They used a murine model (C57BL/6 strain) of RIC and allogeneic hematopoietic stem cell transplantation (HSCT) in which male bone marrow transplanted into female recipient mice induce a host-versus-graft (HvG) reaction against the male specific minor histocompatibility antigen HY. In this system, engraftment could be monitored by RT-PCR and anti-HvG specific effector CD8+ cells using MHC class I tetramer technique. The amount of irradiation therapy prior to HSCT inhibited the generation of HvG effector CD8+ cells in a dose-response fashion. Stable engraftment was achieved following irradiation with 400 cGy but was only temporarily measured at day 14 postHSCT using 200 cGy. The dose-dependent effect of irradiation suggests that donor specific host cells with particular radiosensitivity must be eliminated for successful engraftment. In addition, numbers of HY-specific (anti-donor) CD8+ cells correlated inversely with levels of donor cell engraftment (9.3% [range 4.5–22.5] vs. 1.5% [range 0–7.6] in non-chimeric and chimeric recipients, respectively; P=0.007). The functional competence of HvG effectors was studied in vitro using splenocytes from female C57BL/6 mice transplanted with syngeneic male bone marrow that were stimulated with irradiated male splenocytes. After 7 days of culture, the numbers of HY-specific IFNγ producing CD8+ T cells were greatly expanded in recipients that rejected male bone marrow. Cultured splenocytes from recipients rejecting male bone marrow effectively killed target cells in antigen-specific manner. Neither HY-specific T-cell expansion nor killing was observed when splenocytes from chimeric recipients were assessed. Thus, clear correlation was found between the presence of mixed chimerism and the absence of HvG with engraftment. One would suggest a clonal deletion mechanism for HvG tolerance, but the contribution of regulatory T cells cannot be excluded. The authors also demonstrated that persistent chimerism was associated with tolerance to a second donor graft of hematopoietic or non-hematopoietic (donor type skin) origin. This tolerance was specific since a third party skin graft from CBA/Ca H2k strain was rejected. In addition, by using a congenic strain of mice it was shown that engrafted recipients not only maintained significant proportions of endogenous T cells, but these cells retained functional competence to third party transplantation antigens.